MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks Positive Part 3B Interim Data Presented at Precision Liver Symposium Demonstrated Statistically Significant 68.1% Placebo-Adjusted Reduction in Liver Fat Full...